News & Blog

Iwamura H, Koie T, Soma O, Matsumoto T, Imai A, Hatakeyama S, Yoneyama T, Hashimoto Y, Ohyama C. Eviprostat has an identical effect compared to pollen extract (Cernilton) in patients with chronic prostatitis/chronic pelvic pain syndrome: a randomized, prospective study. BMC Urol. 2015 Dec 7;15:120. doi: 10.1186/s12894-015-0115-5.

Eviprostat is a non-pharmacologic treatment composed of several plant extracts that has been used in Japan and Germany for several decades now as a treatment of men with benign prostatic hyperplasia (BPH). Eviprostat is also potentially effective as a treatment for prostatitis, results of animal studies suggest. Accordingly, investigators in the present study sought to determine whether Eviprostat could offer symptom relief in patients with inflammatory prostatitis/chronic pelvic pain syndrome (CP/CPPS). To test this hypothesis, they compared Eviprostat with another non-pharmacologic treatment known as Cernilton, which is a pollen extract. The study included 100 men with category III CP/CPPS who were randomly assigned to 8 weeks of oral therapy with either Eviprostat or Cernilton. At the end of the 8-week treatment period, both groups had a marked reduction in prostatitis symptoms, with a response rate of about 88% in the Eviprostat group, and a similar 78% response rate in the Cernilton group. Moreover, quality of life was similar between the two groups, and neither treatment resulted in any severe adverse effects. Given the finding that Eviprostat offers comparable symptom relief compared with the pollen extract, men with CP/CPPS might now have another non-pharmacologic option available to them for management of their symptoms.